The Erythrocyte, a Novel Disease-Mediator for COVID-19 Vasculopathy?

Brugnara, Carlo

doi:10.1016/j.jacbts.2022.01.012

Cited by 1 publication

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, patients with pulmonary lesions had higher RBC aggregation and enhanced coagulation [25]. More recently, erythrocyte reactive oxygen species (ROS) production was shown to be increased and NO release to be decreased in COVID-19 vasculopathy [26,27]. Collectively, it appears that erythrocytes may serve an important role in microcirculation and tissue hypoxia in critical illness and particularly in severe COVID-19.…”

Section: Tissue Hypoxia: a Unifying Pathophysiologic Mechanism In Myo...mentioning

confidence: 99%

“…The ESR is considered an indirect index of erythrocyte aggregation and red blood cell rheology, and thus, these data may indicate a potential effect of LT3 on red cell aggregation, which merits further investigation. Erythrocyte aggregation is an important pathophysiologic mechanism in the vasculopathy of COVID-19, and effective treatments targeting red blood aggregation are not currently available [26].…”

Section: Th Therapy In Severe Covid-19: Preliminary Clinical Evidencementioning

confidence: 99%

See 1 more Smart Citation

The Potential of Thyroid Hormone Therapy in Severe COVID-19: Rationale and Preliminary Evidence

Mourouzis

Apostolaki

Trikas

et al. 2022

IJERPH

View full text Add to dashboard Cite

Tissue hypoxia is one of the main pathophysiologic mechanisms in sepsis and particularly in COVID-19. Microvascular dysfunction, endothelialitis and alterations in red blood cell hemorheology are all implicated in severe COVID-19 hypoxia and multiorgan dysfunction. Tissue hypoxia results in tissue injury and remodeling with re-emergence of fetal programming via hypoxia-inducible factor-1α (HIF-1a)-dependent and -independent pathways. In this context, thyroid hormone (TH), a critical regulator of organ maturation, may be of relevance in preventing fetal-like hypoxia-induced remodeling in COVID-19 sepsis. Acute triiodothyronine (T3) treatment can prevent cardiac remodeling and improve recovery of function in clinical settings of hypoxic injury as acute myocardial infarction and by-pass cardiac surgery. Furthermore, T3 administration prevents tissue hypoxia in experimental sepsis. On the basis of this evidence, the use of T3 treatment was proposed for ICU (Intensive Care Unit) COVID-19 patients (Thy-Support, NCT04348513). The rationale for T3 therapy in severe COVID-19 and preliminary experimental and clinical evidence are discussed in this review.

show abstract

Section: Tissue Hypoxia: a Unifying Pathophysiologic Mechanism In Myo...mentioning

confidence: 99%

Section: Th Therapy In Severe Covid-19: Preliminary Clinical Evidencementioning

confidence: 99%

The Potential of Thyroid Hormone Therapy in Severe COVID-19: Rationale and Preliminary Evidence

Mourouzis

Apostolaki

Trikas

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

The Erythrocyte, a Novel Disease-Mediator for COVID-19 Vasculopathy?

Cited by 1 publication

References 7 publications

The Potential of Thyroid Hormone Therapy in Severe COVID-19: Rationale and Preliminary Evidence

The Potential of Thyroid Hormone Therapy in Severe COVID-19: Rationale and Preliminary Evidence

Contact Info

Product

Resources

About